TOKUSHIMA, Japan
Delta-Fly Pharma, Inc. (TOKYO: 4598) announces that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927.
DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed Acute Myelogenous Leukemia. A Phase 3 clinical study at MD Anderson Cancer Center in Texas, USA and other sites in the USA is underway.
Two patients at UT Southwestern Medical Center in Texas and Banner MD Anderson Cancer Center in Arizona registered for this study in November 2019.
In addition, a Phase 1 clinical study of DFP-14927, the polymeric delivery of DFP-10917 in patients with advanced solid tumors has been initiated at MD Anderson Cancer Center.
Two patients registered for this study in October of this year and treatment is ongoing.
|
Company’s profile |
||||
|
Company name |
Delta-Fly Pharma, Inc. [TOKYO:4598] |
|||
|
Capital |
2849 million Japanese Yen |
|||
|
Name and Title of Representative |
Kiyoshi Eshima, PhD, President |
|||
|
Date of Incorporation |
December 6, 2010 |
|||
|
Description of Business |
Research and development, manufacturing and marketing of pharmaceuticals |
|||
|
Head Office |
37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan |
|||
|
Branch Office |
Tokyo, Beijing, Vancouver |
|||
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005329/en/
CONTACT
Delta-Fly Pharma, Inc.
Inquiries: Yasuo Matsueda
TEL: +81-(0)3-6231-1278
ymatsueda1206@delta-flypharma.co.jp
https://www.delta-flypharma.co.jp/
